Shenzhen Siken 3D Technology Development Co., Ltd.

Medical device company · Dongguan, Guangdong, China

Shenzhen Siken 3D Technology Development Co., Ltd. is a medical device company with a registered site in Dongguan, Guangdong, China. The US FDA lists 1 medical device site registered to the company, with devices in general and plastic surgery, neurology and physical medicine.

Profile compiled from public records. Is this your company? Request a correction or update

Shenzhen Siken 3D Technology Development at a glance

Typemedical device company
Registered siteDongguan, Guangdong, China
FDA-registered sites1

What does Shenzhen Siken 3D Technology Development do?

Medical specialties of its FDA-listed devices

General and Plastic SurgeryNeurologyPhysical Medicine

Device types listed with the FDA

Light based over-the-counter hair removalStimulator, transcutaneous electrical, aesthetic purposesLight based over the counter wrinkle reductionMassager, therapeutic, electricLamp, infrared, therapeutic heatingOver-the-counter powered light based laser for acne

Where is Shenzhen Siken 3D Technology Development located?

Registered site: Dongguan, Guangdong, China

  • Dongguan, GuangdongShenzhen Siken 3D Technology Development Co., Ltd. · FDA device site

Frequently asked questions about Shenzhen Siken 3D Technology Development

Where is Shenzhen Siken 3D Technology Development based?

Shenzhen Siken 3D Technology Development Co., Ltd. is based in Dongguan, Guangdong, China.

What does Shenzhen Siken 3D Technology Development do?

Shenzhen Siken 3D Technology Development Co., Ltd. is a medical device company. Its FDA-listed medical devices fall under general and plastic surgery, neurology and physical medicine.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-23. Data licences

Shenzhen Siken 3D Technology Development: Headquarters, Locations & Company Profile (2026) | BioBridgeX